Showing results (361-370 of 392) with videos related to
Sort By:
Pageof 40
The Lancet. Haematology|May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.Blood|September 6, 2013
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndromeEkaterina Chigrinova, Andrea Rinaldi, Ivo Kwee, et al.Blood|August 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLOthman Al-Sawaf, Moritz Fürstenau, Adam Giza, et al.Lancet (London, England)|May 5, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Jeanette Doorduijn, Eva Giné, et al.Lancet (London, England)|May 14, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL NetworkMartin Dreyling, Jeanette Doorduijn, Eva Giné, et al.Lancet (London, England)|December 24, 2019
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialViola Poeschel, Gerhard Held, Marita Ziepert, et al.Proceedings of the National Academy of Sciences of the United States of America|September 10, 2015
MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cellsGero Doose, Andrea Haake, Stephan H Bernhart, et al.Nature Communications|January 19, 2023
Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosisJulien Broséus, Sébastien Hergalant, Julia Vogt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE TrialMarco Ladetto, Katja Gutmair, Rita Tavarozzi, et al.Blood Cancer Discovery|December 5, 2022
In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic VulnerabilitiesElisa Ten Hacken, Tomasz Sewastianik, Shanye Yin, et al.Pageof 40